Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

By E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, G. Kristensen, R. Sorio, I. Vergote, P. Witteveen, A. Bamias and 7 more. Journal of Clinical Oncology, 2014

1,477 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/3c469317ffc39eab92ca3270d1d2578a7293e3f1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. A. Adamis
2. N. Ferrara
3. Jonathan A. Ledermann
4. C. Sessa
5. D. Querleu
6. Rakesh K. Jain
7. Peter Carmeliet
8. R. Apte

In Oncology

1. A. Adamis
2. N. Ferrara
3. Daniel Chen
4. R. Apte

In Reproductive Medicine

1. Jonathan A. Ledermann
2. C. Sessa
3. D. Querleu

Citations in the corpus

• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, background): “2% of patients receiving bevacizumab developed a gastrointestinal perforation.(23) The patient-reported outcomes (PROs) analysis of the study shows that chemotherapy combined with bevacizumab improved gastrointestinal symptoms more often compared with chemotherapy alone, especially in patients with ”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Significant increases in PFS and a trend to improved OS in the Phase III study AURELIA 90 led to FDA approval of bevacizumab, in combination with chemotherapy, for platinum-resistant ovarian cancer in November 2014.”